logo
#

Latest news with #RichardLipscombe

$6M boost to drive industrial-scale Proteomics facility in WA
$6M boost to drive industrial-scale Proteomics facility in WA

The Age

time2 days ago

  • Business
  • The Age

$6M boost to drive industrial-scale Proteomics facility in WA

Proteomics International will expand its Perth facility into a national diagnostics hub using a $6 million funding boost to develop a new protein biomarker analysis platform for industrial-scale precision medical and agricultural screening. The company will partner with The University of Western Australia (UWA), the Western Australian Government and life science research collaborator BioPlatforms Australia to develop its world-class Perth facility. The partners want to target a growing market for high-throughput precision diagnostics across medicine and agriculture. Proteomics and UWA will each kick $1 million into the kitty for the three-year project to develop an accredited protein biomarker analysis platform capable of helping push advances in the two critical sectors. The Proteomics and UWA laboratories collaborate to bring together scientific and technological know-how to tease out the answers to everyday problems in health, agriculture and environmental sciences respectively, focusing on the emerging proteomics field. Proteomics researchers work on identifying and measuring the changes in proteins within cells. Unlike DNA, proteins can change - studying them allows scientists to develop diagnostic tests that can detect diseases earlier and allow doctors to tailor treatments to their patients. 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics.' Proteomics International managing director Dr Richard Lipscombe In agriculture, it could be used to guide grain selection or sowing decisions to improve yield and sustainability, for example. This may become particularly significant given the world's growing population and drying climate, which means farmers must increasingly work to maximise yields while they safeguard crops against drought, salinity, weeds and pests. Proteomics International managing director Dr Richard Lipscombe said: 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics. Extending our recent successful capital raise with state-of-the-art infrastructure to analyse thousands of samples at industrial scale, we can turn biological insight into real-world solutions - whether that's improving outcomes for patients with chronic diseases or selecting better crop varieties to address food security.' Proteomics says achieving a new nationally accredited technology platform would significantly boost the facility's capacity for fast and accurate screening, help roll out diagnostic tests for clinical use and enable it to test large sets of agricultural and environmental samples.

$6M boost to drive industrial-scale Proteomics facility in WA
$6M boost to drive industrial-scale Proteomics facility in WA

Sydney Morning Herald

time2 days ago

  • Business
  • Sydney Morning Herald

$6M boost to drive industrial-scale Proteomics facility in WA

Proteomics International will expand its Perth facility into a national diagnostics hub using a $6 million funding boost to develop a new protein biomarker analysis platform for industrial-scale precision medical and agricultural screening. The company will partner with The University of Western Australia (UWA), the Western Australian Government and life science research collaborator BioPlatforms Australia to develop its world-class Perth facility. The partners want to target a growing market for high-throughput precision diagnostics across medicine and agriculture. Proteomics and UWA will each kick $1 million into the kitty for the three-year project to develop an accredited protein biomarker analysis platform capable of helping push advances in the two critical sectors. The Proteomics and UWA laboratories collaborate to bring together scientific and technological know-how to tease out the answers to everyday problems in health, agriculture and environmental sciences respectively, focusing on the emerging proteomics field. Proteomics researchers work on identifying and measuring the changes in proteins within cells. Unlike DNA, proteins can change - studying them allows scientists to develop diagnostic tests that can detect diseases earlier and allow doctors to tailor treatments to their patients. 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics.' Proteomics International managing director Dr Richard Lipscombe In agriculture, it could be used to guide grain selection or sowing decisions to improve yield and sustainability, for example. This may become particularly significant given the world's growing population and drying climate, which means farmers must increasingly work to maximise yields while they safeguard crops against drought, salinity, weeds and pests. Proteomics International managing director Dr Richard Lipscombe said: 'This facility can become a national hub for precision diagnostic testing across clinical and agricultural proteomics. Extending our recent successful capital raise with state-of-the-art infrastructure to analyse thousands of samples at industrial scale, we can turn biological insight into real-world solutions - whether that's improving outcomes for patients with chronic diseases or selecting better crop varieties to address food security.' Proteomics says achieving a new nationally accredited technology platform would significantly boost the facility's capacity for fast and accurate screening, help roll out diagnostic tests for clinical use and enable it to test large sets of agricultural and environmental samples.

Milestone first patent for Proteomics simple endometriosis test
Milestone first patent for Proteomics simple endometriosis test

The Age

time3 days ago

  • Health
  • The Age

Milestone first patent for Proteomics simple endometriosis test

In a milestone moment, ASX-listed diagnostics innovator Proteomics International Laboratories has achieved its first patent globally in Japan for its simple 'traffic light' diagnostic blood test for endometriosis. The decision will protect the company's intellectual property rights for its PromarkerEndo technology in the world's fourth-largest healthcare market until March 16, 2041. Proteomics says Japan's healthcare sector already widely uses in vitro diagnostics and precision medicine technologies to customise treatments for patients and help deliver better patient outcomes. The company is planning to start an international commercial roll-out of the device within months using its existing direct-to-consumer channels, while also tapping into general practitioners and women's health specialists. 'This is a significant achievement because it validates the novelty of PromarkerEndo, our world-first blood test for endometriosis.' Proteomics International managing director Dr Richard Lipscombe Proteomics International managing director Dr Richard Lipscombe said: 'Securing patent protection for our diagnostic technology in this region is a key step in our global commercialisation pathway and provides a strong foundation for potential partnerships, licensing, and regulatory advancement.' PromarkerEndo promises to revolutionise women's reproductive healthcare by delivering the first clinically viable, real-world, non-invasive diagnostic test for a disease affecting one in nine women and girls. Estimates suggest endometriosis costs the Australian economy nearly $10 billion annually. Its symptoms can be devastating for women, but it has historically been difficult to diagnose. It can take up to seven years on average for women to be diagnosed with endometriosis, using painful and invasive laparoscopy and tissue biopsies, performed under anaesthetics. For the first time, doctors may instead be able to turn to PromarkerEndo as a frontline tool in detecting endometriosis in symptomatic patients. The device uses a universal 'traffic light' risk score - low, moderate or high - to indicate a patient's likelihood of having the disease.

Milestone first patent for Proteomics simple endometriosis test
Milestone first patent for Proteomics simple endometriosis test

Sydney Morning Herald

time3 days ago

  • Health
  • Sydney Morning Herald

Milestone first patent for Proteomics simple endometriosis test

In a milestone moment, ASX-listed diagnostics innovator Proteomics International Laboratories has achieved its first patent globally in Japan for its simple 'traffic light' diagnostic blood test for endometriosis. The decision will protect the company's intellectual property rights for its PromarkerEndo technology in the world's fourth-largest healthcare market until March 16, 2041. Proteomics says Japan's healthcare sector already widely uses in vitro diagnostics and precision medicine technologies to customise treatments for patients and help deliver better patient outcomes. The company is planning to start an international commercial roll-out of the device within months using its existing direct-to-consumer channels, while also tapping into general practitioners and women's health specialists. 'This is a significant achievement because it validates the novelty of PromarkerEndo, our world-first blood test for endometriosis.' Proteomics International managing director Dr Richard Lipscombe Proteomics International managing director Dr Richard Lipscombe said: 'Securing patent protection for our diagnostic technology in this region is a key step in our global commercialisation pathway and provides a strong foundation for potential partnerships, licensing, and regulatory advancement.' PromarkerEndo promises to revolutionise women's reproductive healthcare by delivering the first clinically viable, real-world, non-invasive diagnostic test for a disease affecting one in nine women and girls. Estimates suggest endometriosis costs the Australian economy nearly $10 billion annually. Its symptoms can be devastating for women, but it has historically been difficult to diagnose. It can take up to seven years on average for women to be diagnosed with endometriosis, using painful and invasive laparoscopy and tissue biopsies, performed under anaesthetics. For the first time, doctors may instead be able to turn to PromarkerEndo as a frontline tool in detecting endometriosis in symptomatic patients. The device uses a universal 'traffic light' risk score - low, moderate or high - to indicate a patient's likelihood of having the disease.

Proteomics flags US rollout of kidney test at global diabetes summit
Proteomics flags US rollout of kidney test at global diabetes summit

Sydney Morning Herald

time20-06-2025

  • Health
  • Sydney Morning Herald

Proteomics flags US rollout of kidney test at global diabetes summit

ASX-listed diagnostics disruptor Proteomics International has officially launched its innovative kidney disease test, PromarkerD, in the massive United States healthcare market. The launch took place at the American Diabetes Association's 85th scientific sessions talkfest in Chicago. The annual conference marks the world's largest gathering of diabetes experts, making it the ideal stage to unveil PromarkerD to the US market. PromarkerD is a simple predictive blood test capable of identifying a person's risk of developing diabetic kidney disease (DKD) up to four years before symptoms appear, offering a potential lifeline to the more than 32 million Americans living with type 2 diabetes. According to clinical studies, the patented test accurately predicted kidney function decline in up to 86 per cent of patients who otherwise showed no symptoms. 'This marks a significant milestone in our global commercialisation strategy.' Proteomics International managing director Dr Richard Lipscombe More than half of all adults with diabetes in the US will develop kidney complications. These cases contribute to a colossal US$130 billion in annual healthcare costs - more than a quarter of the nation's Medicare budget. Proteomics International managing director Dr Richard Lipscombe said: 'We're excited to introduce PromarkerD to the US at such a prestigious event. This marks a significant milestone in our global commercialisation strategy and underscores our commitment to addressing the diabetes epidemic through precision medicine.' The PromarkerD rollout will begin in California, supported by the company's recently commissioned CLIA-certified testing laboratory in Irvine. US patients will be able to access the test from Proteomics International's integrated digital health platform. The sales model was piloted in Australia and designed to support direct-to-consumer and clinical engagement. Renowned diabetes professional Davida Kruger, from Henry Ford Health in Detroit, called the test 'a paradigm shift in diabetes care.' Kruger noted early identification of at-risk patients means doctors can use preventive strategies long before irreversible damage occurs.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store